Recombinant Human Heat Shock Protein Hsp 90-Alpha (HSP90AA1) Protein (His-SUMO)

Beta LifeScience SKU/CAT #: BLC-03445P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Heat Shock Protein Hsp 90-Alpha (HSP90AA1) Protein (His-SUMO)

Beta LifeScience SKU/CAT #: BLC-03445P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description Recombinant Human Heat Shock Protein Hsp 90-Alpha (HSP90AA1) Protein (His-SUMO) is produced by our E.coli expression system. This is a protein fragment.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb P07900
Target Symbol HSP90AA1
Synonyms Heat shock 86 kDa; Heat shock protein 90kDa alpha cytosolic class A member 1; Heat shock protein 90kDa alpha cytosolic class B member 1; Heat shock protein HSP 90 alpha ; Heat shock protein HSP 90 beta; Heat shock protein HSP 90-alpha; HS90A_HUMAN; HSP 84; HSP 86; Hsp 90; HSP86; HSP90A; HSP90AA1; HSP90AB1; HSP90B; HSPC1; HSPC2; HSPCAL1 ; HSPCAL4; Renal carcinoma antigen NY-REN-38
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His-SUMO
Target Protein Sequence DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSD
Expression Range 9-232aa
Protein Length Partial
Mol. Weight 41.2kDa
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function. Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle. Plays a critical role in mitochondrial import, delivers preproteins to the mitochondrial import receptor TOMM70. Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues(PubMed:25973397). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation. Mediates the association of TOMM70 with IRF3 or TBK1 in mitochodria outer membrane which promotes host antiviral response.
Subcellular Location Nucleus. Cytoplasm. Melanosome. Cell membrane. Mitochondrion. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
Protein Families Heat shock protein 90 family
Database References

Gene Functions References

  1. RPAP3 provides a flexible scaffold for coupling HSP90 to the human R2TP co-chaperone complex. PMID: 29662061
  2. The study shows that a conserved tryptophan in the middle domain senses the interaction of Hsp90 with a stringent client protein and transfers this information via a cation-pi interaction with a neighboring lysine. PMID: 29662162
  3. While activation in c-Src is strictly controlled by ATP-binding and phosphorylation, the authors find that activating conformational transitions are spontaneously sampled in Hsp90-dependent Src mutants. PMID: 28290541
  4. chemotherapy agents can induce HSP90AA1 expression in osteosarcoma cells. And HSP90AA1, acting as an important regulator of autophagy, is a critical factor in the development of osteosarcoma chemoresistance both in vitro and in vivo. HSP90AA1 provides a novel therapeutic target for improving osteosarcoma treatment. PMID: 30153855
  5. We confirm that miR-628-3p promotes apoptosis and inhibits migration in A549 cells by negatively regulating HSP90. Our results may reveal a novel strategy for lung cancer treatment PMID: 29888262
  6. Data recognize HSP90 as a novel binding partner of PKM2 in hepatocellular carcinoma (HCC) cells. HSP90 potentiates the glycolysis and proliferation, reduces the apoptosis and thus enhances the growth of HCC cells through PKM2 Thr-328 phosphorylation maintaining its stability. PMID: 29262861
  7. EGFR expression stratified most pronounced among HSP90low tumours, where the EGFRhigh phenotype was associated with longer survival PMID: 28765916
  8. the SGT1-HSP90 complex contributes to the E3 ligase activity of the CUL4A complex that is necessary for CENP-A ubiquitylation and CENP-A deposition at the centromere. PMID: 28816574
  9. our data suggested that Hsp90alpha could positively regulate the self-renewal of BCSCs by facilitating the nuclear translocation of c-Myc and EZH2 to maintain BMI1 expression. PMID: 28914785
  10. HSP90 contributes to cutaneous vasodilation via NOS-dependent mechanisms in young habitually active men during exercise in the heat. PMID: 28751373
  11. The association between the MEEVD C-terminal peptide from the heat shock protein 90 (Hsp90) and tetratricopeptide repeat A (TPR2A) domain of the heat shock organizing protein (Hop) is a useful prototype to study the fundamental molecular details about the Hop-Hsp90 interaction. Observed are conformational changes of the peptide and the protein receptor induced by binding. The binding free energy is 8.4 kcal/mol. PMID: 28723223
  12. Our findings demonstrate Hsp90 blockade leads to ICN1 destabilization, providing an alternative strategy to antagonize oncogenic Notch1 signaling with Hsp90-selective inhibitors PMID: 28143869
  13. Generated multiple mutant KRAS-driven cancer cell lines with acquired resistance to the purine-scaffold HSP90 inhibitor PU-H71. Report a Y142N missense mutation in the ATP-binding domain of HSP90alpha that co-occurred with amplification of the HSP90AA1 locus in resistant cells. PMID: 28032595
  14. ATM is the primary kinase responsible for phosphorylation of Hsp90alpha after exposure ionizing radiation. PMID: 27738310
  15. molecular modeling was employed to incorporate experimental data using partial constructs of the Hsp90 C-terminal domain. PMID: 27771574
  16. findings suggested that this mechanism may be exploited by the Hsp90-Cdc37 chaperone to recruit and protect intrinsically dynamic kinase clients from degradation PMID: 29267381
  17. The findings establish an active role for Tsc1 as a facilitator of Hsp90-mediated folding of kinase and non-kinase clients-including Tsc2-thereby preventing their ubiquitination and proteasomal degradation. PMID: 29127155
  18. Data indicate HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy. PMID: 28878208
  19. Data suggest that SOCS3 is an important signaling protein in CLL, and Hsp90 inhibitors represent an approach to target transcriptional repression in B cell lymphoproliferative disorders. PMID: 27107422
  20. FKBP51 is primarily localized in mitochondria and hTERT is totally nuclear, upon the onset of oxidative stress, FKBP51 (but not FKBP52) becomes mostly nuclear colocalizing with hTERT, and longer exposure times to peroxide favors hTERT export to mitochondria. PMID: 27233944
  21. High HSP90 expression is associated with Colorectal Cancers. PMID: 28870917
  22. High HSP90 expression is associated with prostate cancer. PMID: 28038472
  23. Data suggest HSP90AA1-dependent regulation of ATM-NBN-CHK2 and ATR-CHK1 axes influences cells capability to repair double-stranded DNA damage; mechanisms include phosphorylation, polyubiquitination, and proteasomal degradation/proteolysis. (HSP90AA1 = heat shock protein 90kDa alpha; ATM = ataxia telangiectasia mutated protein; NBN = nibrin; CHK = checkpoint kinase; ATR = ataxia telangiectasia and Rad3 related kinase) PMID: 28631426
  24. Data show that pyruvate kinase M2 (PKM2) directly interacted with mutant growth factor receptor (EGFR) and heat-shock protein 90 (HSP90), and thus stabilized EGFR by maintaining its binding with HSP90 and co-chaperones. PMID: 26500058
  25. Binding of FM807 to the N-terminus of Hsp90 disrupted Hsp90/client complexes, resulting in degradation of the Hsp90 client protein EGFR and inhibition of the downstream pathway. PMID: 28157708
  26. Conventional as well as scaled molecular dynamics simulations further demonstrate that citrullination of selected Arg residues leads to progressive disruption of HSP90 tertiary structure, promoting exposure of R502/R510 to PAD modification and subsequent autoantibody binding. PMID: 27448590
  27. SYK is an HSP90 client protein, and B-cell receptor signaling-dependent phosphorylation of HSP90 on Y197 is required for this interaction. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. PMID: 28064214
  28. Data indicate a chaperone function of nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2), independent from its enzymatic activity, and NMNAT2 complexes with heat shock protein 90 (HSP90) to refold aggregated protein substrates. PMID: 27254664
  29. In the bound state, the Hsp90 dimer predominantly populates an open conformation, and transthyretin retains its globular structure. PMID: 28218749
  30. CD30 facilitates phosphorylation of heat shock factor 1, activates heat shock promoter element, and induces heat shock protein (HSP) 90. PMID: 27870927
  31. However, once the mumps virus L protein formed a mature polymerase complex with the P protein, Hsp90 activity was no longer required for the stability and activity of the L protein. PMID: 28053100
  32. HSP90 may be essential for stabilization and function of P2X7Rs through an action on the cysteine-rich domain of the cytoplasmic the C-terminus. PMID: 27301716
  33. HSP90AA1 and AB1 genes exhibit low expression in breast cancers highly sensitive to chemotherapy and may indicate the patients with higher probability of pathological complete response. PMID: 28051275
  34. the effect of HSP90 inhibition on IL-17-mediated cytokine and antimicrobial peptide expression in keratinocytes following heat treatment, was examined. PMID: 27279135
  35. epididymis secretory protein 4 had better specificity than CA125 in discriminating ovarian cancer, and endometrial cancer from benign gynecological diseases in southern China population PMID: 27302312
  36. Hsp90 has roles in the regulation of autophagy, such as toll-like receptor (TLR)-mediated autophagy, Ulk1-mediated mitophagy, and chaperone-mediated autophagy (CMA) [review] PMID: 26432328
  37. this study identified HSP90AA1 as a new potential biomarker for Behcet's disease by comparing highly ranked genes from all the built network-derived gene lists, which was confirmed the with real-world clinical samples PMID: 27226232
  38. Data show that heat shock protein 90 (HSP90) inhibitor 17-DMAG caused loss of ret proto-oncogene protein (RET) and proto-oncogene protein erbB-3 (ERBB3) phosphorylation and lead to rapid cell death. PMID: 26595521
  39. Hsp103 associates with cochaperone proteins, such as Hop, Cdc37 and Aha1, similar to Hsp90. The extra domain reduces the ATP hydrolysis when compared to Hsp90 thereby acting as a negative regulator of the chaperones intrinsic ATPase activity. PMID: 23951259
  40. Data suggest that synergistic mechanism between heat shock protein 90 (Hsp90) inhibitor SNX-7081 and fludarabine nucleoside (2-FaraA) may provide an alternative treatment for chronic lymphocytic leukemia (CLL) patients with p53 protein mutations. PMID: 26556860
  41. The expression of HSP90A was increased in the HCC cells, serum, and tissues. Immunohistochemistry analysis on 76 clinical tissue samples also suggested the relevance between HSP90A expression and HCC metastatic behavior. PMID: 26704341
  42. Aarsd1 inhibits the activity of a paradigmatic Hsp90 client protein. PMID: 26884463
  43. study confirmed Hsp90 as an influenza virus A PB2 polymerase interacting protein, and established that Hsp90 interacts with both the E627 and 627K variants, but has established this interaction is species independent, and both mammalian and avian Hsp90 can bind to the PB2 protein PMID: 26616658
  44. Data show that high-affinity heat shock protein 90 (HSP90) binding conferred by the inhibitor backbone could be exploited for conjugate accumulation within tumor cells. PMID: 26271675
  45. In conjunction with HSP90, the cytoplasmic USP19 may play a key role in triage decision for the disease-related polyQ-expanded substrates, suggesting a function of USP19 in quality control of misfolded proteins by regulating their protein levels PMID: 26808260
  46. The region of aa 250-295 of BGLF4 is essential for the BGLF4/Hsp90 interaction. PMID: 26982469
  47. The thermodynamics of binding of Cyp-40 to Hsp90 shows remarkable temperature sensitivity in the physiological temperature range. PMID: 26330616
  48. HSP90 overexpression is a prognostic marker for cholangiocarcinoma. HSP90-targeted therapy may be an option for a subset of cholangiocarcinoma. PMID: 26141945
  49. From our screening methodology, we identified HCAb2 as a breast tumor specific heavy chain antibody targeting cell surface heat shock protein 90. PMID: 26334999
  50. Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita. PMID: 25739426

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed